Epigenetic Regulation of BDNF in Major Depression
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01182103|
Recruitment Status : Completed
First Posted : August 16, 2010
Results First Posted : August 15, 2014
Last Update Posted : August 15, 2014
|Condition or disease|
|Major Depressive Disorder|
Brain-derived neurotrophic factor (BDNF) had been chosen as a candidate gene for a development of major depressive disorder (MDD). BDNF had been reported to have an important role on neuronal plasticity, axonal growth and connectivity, and participating in the local response to various types of neuronal stressors. BDNF also influences the differentiation of neurons.
In the past studies, the investigators had found that major depressive women had lower serum BDNF protein levels than healthy controls, and their BDNF levels became significantly increased after antidepressant treatments. In addition, some authors had found that reduced expression of BDNF was noted in postmortem brain of completed suicide subjects. Suicidal major depressive patients also had lower plasma BDNF levels than non-suicidal major depressive patients. These findings suggested that BDNF might play an important role in the suicidal behavior.
However, in past studies, the results did not fully explain why major depressive patients with same genotypes had different clinical expression, including the severity of depression, with/without suicide, and the treatment response. Recently, some papers found that there were relationships between epigenetic regulation, including DNA methylation and histone modification, and psychopathology of major depression. Therefore, we try to investigate the relationships between epigenetic regulation of BDNF and major depression.
|Study Type :||Observational|
|Actual Enrollment :||110 participants|
|Observational Model:||Case Control|
|Official Title:||Epigenetic Regulation of Brain-Derived Neurotropic Factor (BDNF) in Patients With Major Depression|
|Study Start Date :||August 2010|
|Actual Primary Completion Date :||July 2012|
|Actual Study Completion Date :||May 2013|
|Major depressive patients|
- Brain-derived Neurotrophic Factor (BDNF) DNA Methylation of Major Depressive Disorder (MDD) Patients and Healthy Controls [ Time Frame: 2 years ]averaged percentage of methylation at each CpG site listed
- Histone Modification of MDD Patients Before and After Treatment and With Healthy Controls [ Time Frame: 2 years ]
Chromatin immunoprecipitation (ChIP) was used to measure histone modification. The unit of our given machine is relative quantification, and a higher value indicated increased histone modification. The detailed method could be found in:
Huebert DJ, Kamal M, O'Donovan A, Bernstein BE: Genome-wide analysis of histone modifications by ChIP-on-chip. Methods 2006; 40: 365-369.
- BDNF Levels of MDD Patients Before and After Treatment and Healthy Controls [ Time Frame: 2 years ]
Serum BDNF levels were measured. MDD patients received antidepressant treatment, a standard biological management. Nothing novel (such as experimental drugs or management) is introduced in the treatment, so the research design is observational (of standard treatment).
The choice of antidepressant drugs depended on the need of patients in natural treatment procedure. They included selective serotonin reuptake inhibitors (SSRI), eg. fluoxetine or paroxetine.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01182103
|Department of Psychiatry, Chang Gung Memorial Hospital|
|Kaohsiung, Taiwan, 833|
|Principal Investigator:||Tiao-Lai Huang, M.D.||Chang-Gung Memorial Hospital, Kaohsiung|